Isomorphic Labs

An AI drug design engine (IsoDDE) that goes beyond AlphaFold-style structure prediction to design molecules across therapeutic areas and modalities; Alphabet spinout run by Demis Hassabis.

Founded

November 2021

Headquarters

London, UK

Founders

Demis Hassabis

Pushes against

Drug discovery as a screening-heavy wet-lab process.

Now

Raised $2.1B Series B (2026-05-12), led by Thrive. Advancing drug design programs across multiple therapeutic areas; I did not find a clinical-stage milestone in sources I opened.

Key people

• Demis Hassabis (founder, CEO)

Funding

• 12 May 2026

  Amount

  $2.1B Series B

  Lead

  Thrive Capital (Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund)

  Source isomorphiclabs.com
• 31 March 2025

  Amount

  $600M, first external round

  Lead

  Thrive Capital (GV; Alphabet follow-on)

  Source isomorphiclabs.com

Every funding round in the atlas

Sources

1. isomorphiclabs.com/articles/isomorphic-labs-announces-series-b-investment-round
2. isomorphiclabs.com/articles/isomorphic-labs-announces-600m-external-investment-round
3. en.wikipedia.org/wiki/Isomorphic_Labs

This profile was checked and corrected against its sources on 6 October 2026. How we check